Haolu Wang

Haolu Wang

Auto-generated profile, based on publicly available information

Haolu Wang

Frazer Institute, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, QLD 4102, Australia; Gallipoli Medical Research, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia; Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, QLD 4006, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HYHaotian Yang
Haotian Yang
RVRehan M Villani
Rehan M Villani
HWHaolu Wang
Haolu Wang
MSMatthew J Simpson
Matthew J Simpson
Michael RobertsMichael Roberts
Michael Roberts
XLXiaowen Liang
Xiaowen Liang
Most chemotherapeutics elevate intracellular levels of reactive oxygen species (ROS), and many can alter redox-homeostasis of cancer cells. It is widely accepted that the anticancer effect of these chemotherapeutics is due to the induction of oxidative stress and ROS-mediated cell injury in cancer. However, various new therapeutic approaches targeting intracellular ROS levels have yielded mixed results. Since it is impossible to quantitatively detect dynamic ROS levels in tumors during and after chemotherapy in clinical settings, it is of increasing interest to apply mathematical modeling techniques to predict ROS levels for understanding complex tumor biology during chemotherapy. This review outlines the current understanding of the role of ROS in cancer cells during carcinogenesis and during chemotherapy, provides a critical analysis of the methods used for quantitative ROS detection and discusses the application of mathematical modeling in predicting treatment responses. Finally, we provide insights on and perspectives for future development of effective therapeutic ROS-inducing anticancer agents or antioxidants for cancer treatment.

1 July 2021 in Pharmacological Research
Verified
Journal Article
Closed access
ABAnastasia Brooks
Anastasia Brooks
XLXiaowen Liang
Xiaowen Liang
YZYonglong Zhang
Yonglong Zhang
CZChun-Xia Zhao
Chun-Xia Zhao
MRMichael S. Roberts
Michael S. Roberts
DCDarrell H. G. Henry Gordon Crawford
Darrell H. G. Henry Gordon Crawford

6 December 2018 in PeerJ
Verified
Journal Article
Open access
PDF file
WJWang Jin
Wang Jin
XLXiaowen Liang
Xiaowen Liang
ABAnastasia Brooks
Anastasia Brooks
KFKathryn Futrega
Kathryn Futrega
XLXin Liu
Xin Liu
HWHaolu Wang
Haolu Wang
Background: Mesenchymal stem/stromal cells (MSCs) are a promising tool for cell-based therapies in the treatment of tissue injury. The stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) axis plays a significant role in directing MSC homing to sites of injury. However in vivo MSC distribution following intravenous transplantation remains poorly understood, potentially hampering the precise prediction and evaluation of therapeutic efficacy. Methods: A murine model of partial ischemia/reperfusion (I/R) is used to induce liver injury, increase the hepatic levels of SDF-1, and study in vivo MSC distribution. Hypoxia-preconditioning increases the expression of CXCR4 in human bone marrow-derived MSCs. Quantitative assays for human DNA using droplet digital PCR (ddPCR) allow us to examine the in vivo kinetics of intravenously infused human MSCs in mouse blood and liver. A mathematical model-based system is developed to characterize in vivo homing of human MSCs in mouse models with SDF-1 levels in liver and CXCR4 expression on the transfused MSCs. The model is calibrated to experimental data to provide novel estimates of relevant parameter values. Results: Images of immunohistochemistry for SDF-1 in the mouse liver with I/R injury show a significantly higher SDF-1 level in the I/R injured liver than that in the control. Correspondingly, the ddPCR results illustrate a higher MSC concentration in the I/R injured liver than the normal liver. CXCR4 is overexpressed in hypoxia-preconditioned MSCs. An increased number of hypoxia-preconditioned MSCs in the I/R injured liver is observed from the ddPCR results. The model simulations align with the experimental data of control and hypoxia-preconditioned human MSC distribution in normal and injured mouse livers, and accurately predict the experimental outcomes with different MSC doses. Discussion: The modelling results suggest that SDF-1 in organs is an effective in vivo attractant for MSCs through the SDF-1/CXCR4 axis and reveal the significance of the SDF-1/CXCR4 chemotaxis on in vivo homing of MSCs. This in vivo modelling approach allows qualitative characterization and prediction of the MSC homing to normal and injured organs on the basis of clinically accessible variables, such as the MSC dose and SDF-1 concentration in blood. This model could also be adapted to abnormal conditions and/or other types of circulating cells to predict in vivo homing patterns.

1 August 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
LSLiam Spannenburg
Liam Spannenburg
MGMariana Sanchez Gonzalez
Mariana Sanchez Gonzalez
ABAnastasia Brooks
Anastasia Brooks
SWShujun Wei
Shujun Wei
XLXinxing Li
Xinxing Li
HWHaolu Wang
Haolu Wang

6 December 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAnastasia Brooks
Anastasia Brooks
KFKathryn Futrega
Kathryn Futrega
XLXiaowen Liang
Xiaowen Liang
XHXiaoling Hu
Xiaoling Hu
XLXin Liu
Xin Liu
HWHaolu Wang
Haolu Wang
Mesenchymal stem/stromal cells (MSCs) present a promising tool in cell‐based therapy for treatment of various diseases. Currently, optimization of treatment protocols in clinical studies is complicated by the variations in cell dosing, diverse methods used to deliver MSCs, and the variety of methods used for tracking MSCs in vivo. Most studies use a dose escalation approach, and attempt to correlate efficacy with total cell dose. Optimization could be accelerated through specific understanding of MSC distribution in vivo, long‐term viability, as well as their biological fate. While it is not possible to quantitatively detect MSCs in most targeted organs over long time periods after systemic administration in clinical trials, it is increasingly possible to apply pharmacokinetic modeling to predict their distribution and persistence. This Review outlines current understanding of the in vivo kinetics of exogenously administered MSCs, provides a critical analysis of the methods used for quantitative MSC detection in these studies, and discusses the application of pharmacokinetic modeling to these data. Finally, we provide insights on and perspectives for future development of effective therapeutic strategies using pharmacokinetic modeling to maximize MSC therapy and minimize potential side effects. Stem Cells Translational Medicine 2018;7:78–86

Verified
Journal Article
Open access
PDF file
Raji BaidyaRaji Baidya
Raji Baidya
DCDarrell H. G. Henry Gordon Crawford
Darrell H. G. Henry Gordon Crawford
JGJérémie Gautheron
Jérémie Gautheron
HWHaolu Wang
Haolu Wang
KBKim Bridle
Kim Bridle
While liver transplantation remains the sole treatment option for patients with end-stage liver disease, there are numerous limitations to liver transplantation including the scarcity of donor livers and a rise in livers that are unsuitable to transplant such as those with excess steatosis. Fatty livers are susceptible to ischaemia-reperfusion (IR) injury during transplantation and IR injury results in primary graft non-function, graft failure and mortality. Recent studies have described new cell death pathways which differ from the traditional apoptotic pathway. Necroptosis, a regulated form of cell death, has been associated with hepatic IR injury. Receptor-interacting protein kinase 3 (RIPK3) and mixed-lineage kinase domain-like pseudokinase (MLKL) are thought to be instrumental in the execution of necroptosis. The study of hepatic necroptosis and potential therapeutic approaches to attenuate IR injury will be a key factor in improving our knowledge regarding liver transplantation with fatty donor livers. In this review, we focus on the effect of hepatic steatosis during liver transplantation as well as molecular mechanisms of necroptosis and its involvement during liver IR injury. We also discuss the immune responses triggered during necroptosis and examine the utility of necroptosis inhibitors as potential therapeutic approaches to alleviate IR injury.